Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2026-01-04 @ 2:15 AM
Study NCT ID:
NCT05501769
Status:
COMPLETED
Last Update Posted:
2025-09-26
First Post:
2022-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
Sponsor:
Arvinas Estrogen Receptor, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced breast cancer | View |
| None | Metastatic breast cancer | View |
| None | MBC | View |
| None | Endocrine therapy | View |
| None | Estrogen receptor | View |
| None | ER+ | View |
| None | human epidermal growth factor receptor 2 | View |
| None | HER2- | View |
| None | ARV-471 | View |
| None | Everolimus | View |
| None | PROTAC | View |
| None | Vepdegestrant | View |